semaglutide competitors Canada approves first generic version of Ozempic amid rising GLP-1 competition Compounding Novo Nordisk slashes Wegovy

Clinics are combining peptides with lab results and patient-reported outcomes to design protocols that target aging, recovery, metabolism, or cognition with greater precision

Gholipour, P., Komaki, A., Parsa, H

For Managing Chronic Conditions Individuals dealing with chronic health conditions may require a more tailored and often more frequent approach to glutathione IV therapy

For many, their bodies soon start to adjust to the medications, and these issues subside on their own

While there are varying perspectives on this issue, in a viewpoint that I was pleased to co-author with Sam Klein and Kevin Hall just published in JAMA, we suggest that the concern regarding physical frailty or sarcopenia with GLP-1-based medications may not be as grounded as some argue

Clinically meaningful interactions would not be expected with other sulfonylureas (e.g., glipizide, tolbutamide, and glimepiride) which, like glyburide, are primarily eliminated by CYP2C9 [see Warnings and Precautions]